Data on intraprocedural anticoagulation
The time-course curves of the ACT differed significantly across the patients with apixaban, dabigatran, edoxaban, and rivaroxaban, and its highest levels were seen in the dabigatran group during the time period between the 1st and 4th ACT measurements (Figure 1). The average ACT was greater in the patients with dabigatran than in those with the other DAOCs (312.3±34, 334.4±44, 308.1±41, and 305.8±34.7 sec; P <0.001, Figure 2). Time from the initial heparin injection to the first achievement of the target ACT differed significantly across the patient groups (54.8±25.6, 47.2±21.6, 56.1±26.8, and 50.6±24.1 sec; P=0.02), with its shortest time in the dabigatran group (Figure 2). A significant difference was noted in the total heparin requirement across the patient groups (3990.2±1167.9, 3890.4±955.3, 4423.8±1051.6, and 3972±978.7 U/m2/h; P <0.001), with its greatest amount in the edoxaban group (Figure 3).